Clostridium difficile infection and inflammatory bowel disease: A marker for disease extent?

Gut

Volumn 57, Issue 8, 2008, Pages 1183-1184

  Powell, Nick ^a   Jung, S E ^b   Krishnan, B ^b  

^a IMPERIAL COLLEGE HEALTHCARE NHS TRUST   (United Kingdom)

^b LISTER HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; CYCLOSPORIN; INFLIXIMAB;

BACTERIAL INFECTION; BACTERIUM CULTURE; CLOSTRIDIUM DIFFICILE; DISEASE ASSOCIATION; DISEASE EXACERBATION; DISEASE MARKER; DISEASE SEVERITY; ENTERITIS; FECES ANALYSIS; HOSPITAL ADMISSION; HUMAN; IMMUNOMODULATION; INCIDENCE; INFECTION SENSITIVITY; LETTER; MORBIDITY; MORTALITY; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; ULCERATIVE COLITIS;

CLOSTRIDIUM DIFFICILE; ENTEROCOLITIS, PSEUDOMEMBRANOUS; HUMANS; INFLAMMATORY BOWEL DISEASES; OPPORTUNISTIC INFECTIONS;

EID: 48249135038     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Letter

References (3)

1. Travis SP, Farrant JM, Ricketts C, et al. Predicting outcome in severe ulcerative colitis. Gut 1996;38:905-10.
2. Meyers S, Lerer PK, Feuer EJ, et al. Predicting the outcome of corticoid therapy for acute ulcerative colitis. Results of a prospective, randomized, double-blind clinical trial. J Clin Gastroenterol 1987;9:50-4.
3. Mylonaki M, Langmead L, Pantes A, et al. Enteric infection in relapse of inflammatory bowel disease: importance of microbiological examination of stool. Eur J Gastroenterol Hepatol 2004;16:775-8.